Startseite>>Signaling Pathways>> Immunology/Inflammation>> STING>>diABZI-C2-NH2

diABZI-C2-NH2

Katalog-Nr.GC63473

diABZI-C2-NH2, ein aktives Analogon mit einer primÄren AminfunktionalitÄt, ist ein STING-Agonist.

Products are for research use only. Not for human use. We do not sell to patients.

diABZI-C2-NH2 Chemische Struktur

Cas No.: 2137975-93-8

Größe Preis Lagerbestand Menge
5 mg
702,00 $
Auf Lager
10 mg
1.125,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

diABZI-C2-NH2, an active analogue containing a primary amine functionality, is a STING agonist[1].

The author developed a linking strategy to synergize the effect of two symmetry-related amidobenzimidazole (ABZI)-based compounds to create linked ABZIs (diABZIs) with enhanced binding to STING and cellular function. Intravenous administration of a diABZI STING agonist to immunocompetent mice with established syngeneic colon tumours elicited strong anti-tumour activity, with complete and lasting regression of tumors[1]. diABZI-C2-NH2 is covalently immobilized on sepharose beads and is used to affinity-capture potential target proteins from a THP1 cell lysate[1].

[1]. Ramanjulu JM, et al. Design of amidobenzimidazole STING receptor agonists with systemic activity [published correction appears in Nature. 2019 Jun;570(7761):E53]. Nature. 2018;564(7736):439-443.

Bewertungen

Review for diABZI-C2-NH2

Average Rating: 5 ★★★★★ (Based on Reviews and 33 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for diABZI-C2-NH2

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.